Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -34.07
- Piotroski Score 3.00
- Grade Buy
- Symbol (ENVB)
- Company Enveric Biosciences, Inc.
- Price $0.34
- Changes Percentage (-3.72%)
- Change -$0.01
- Day Low $0.31
- Day High $0.34
- Year High $2.92
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
- Last Earnings 04/07/2008
- Ex-Dividend for 5/16 Dividend 04/23/2008
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.39
- Trailing P/E Ratio -0.12
- Forward P/E Ratio -0.12
- P/E Growth -0.12
- Net Income $-17,292
Income Statement
Quarterly
Annual
Latest News of ENVB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Enveric Biosciences, Inc. (NASDAQ:ENVB) Trading At A 36% Discount?
Enveric Biosciences' intrinsic value is estimated using the Discounted Cash Flow (DCF) model, showing it is undervalued by 36% compared to its current stock price. This method projects future cash flo...
By Yahoo! Finance | 4 months ago